📬 Breast Cancer Intelligence Digest — Week 2026-W34

Tissue-free ctDNA matched tumor-informed MRD assays in early TNBC, ivonescimab plus chemotherapy produced an 80% response rate in first-line TNBC, T-DXd rechallenge showed a 27% ORR in HER2-positive mBC, and SUPREMO, DBCG Skagen Trial 1 and the SERENA-6 update reshaped local therapy and endocrine-switch debates.

⚡ TL;DR

📄 Publications

Tissue-Free vs Tumor-Informed ctDNA Assays for Molecular Residual Disease Detection in Early Triple Negative Breast Cancer. — The analysis included 1026 plasma samples from 159 patients with TNBC at moderate to high risk of recurrence

🐦 Twitter / 🦋 Bluesky

Update: side-by-side reading of RxPONDER, TAILORx and OPTIMA turns into a debate about who OPTIMA actually applies to — RxPONDER, TAILORx and OPTIMA were summarized side by side in an AI-generated comparison circulated among breast oncologists
EN-SEMBLE post-hoc analysis: T-DXd rechallenge after discontinuation gives 27% ORR and no new ILD — Among 664 patients in EN-SEMBLE, 26 patients with HER2-positive mBC were rechallenged with T-DXd, achieving ORR 27%, median rwPFS 6.5 mo and OS 14.2 mo with no ILD on rechallenge
First-line ivonescimab plus chemotherapy hits 80% ORR in advanced TNBC, but the anti-VEGF track record invites caution — First-line ivonescimab plus taxane in advanced TNBC (n=36) produced ORR 80% and mPFS 15.2 mo, with ORR 79.3% and mPFS 13 mo in CPS<10 disease
GLP-1 receptor agonists and breast cancer incidence: a JCO OP signal meets a borderline hazard ratio — GLP-1 agonists are associated with a significant reduction in breast cancer incidence in women according to a JCO Oncology Practice report

Full details below ↓

📄 What's Being Published

Manuscripts:

Tissue-Free vs Tumor-Informed ctDNA Assays for Molecular Residual Disease Detection in Early Triple Negative Breast Cancer. — Cunningham Niamh et al., JAMA Oncol

The analysis included 1026 plasma samples from 159 patients with TNBC at moderate to high risk of recurrence. The tissue-free assay detected ctDNA in 54 patients (34.0%), with detection strongly associated with recurrence risk (HR, 27.2; 95% CI, 13.7–54.2; P < .001). Median lead time to recurrence was 7.9 months for the tissue-free assay versus 5.8 months for dPCR (HR, 0.57; P = .03), while median lead times were 7.6 months with tissue-free and 7.1 months with the multivariant tumor-informed assay (HR, 1.46; P = .15).

Clinical bottom line: Tissue-free methylation-based ctDNA surveillance is prognostically as informative as tumor-informed assays in early TNBC and should be the fallback whenever primary tumor tissue is unavailable for trial-based MRD monitoring.

Read full article →

🗣️ What People Were Discussing This Week

How these are chosen: filtered for clinical relevance, grouped by the new development discussed, then ordered by engagement (bookmarks and reposts).

Update: side-by-side reading of RxPONDER, TAILORx and OPTIMA turns into a debate about who OPTIMA actually applies to

RxPONDER, TAILORx, and OPTIMA were summarized side by side in an AI-generated comparison circulated among breast oncologists, sharpening debate about the applicable population for each dataset. OPTIMA mandated ovarian function suppression for premenopausal women, and follow-up is currently short; OFSET is expected to provide key data, with some clinicians arguing OPTIMA's results apply specifically to women over 40 with N1 disease where chemotherapy benefit was already thought to derive largely from ovarian suppression. The clinical trial EA1241 is separately evaluating tissue samples from past TAILORx and RxPONDER participants who experienced a recurrence to investigate why breast cancer returns after treatment. The central debate remains which gene-expression test should decide chemotherapy in node-positive disease when OPTIMA's premenopausal patients all received ovarian suppression.

Discussed by: @OncBrothers, @eaonc

→ View representative tweet

EN-SEMBLE post-hoc analysis: T-DXd rechallenge after discontinuation gives 27% ORR and no new ILD

A post-hoc analysis of EN-SEMBLE (N=664) identified 26 patients with HER2-positive metastatic breast cancer who were rechallenged with T-DXd, yielding an ORR of 27%, median real-world PFS of 6.5 months, and OS of 14.2 months, with longer rwPFS observed in patients who had stopped T-DXd for reasons other than progression and no ILD events on rechallenge. Separately, a mechanistic analysis framed HER2-ADC resistance as extending beyond target loss to impaired internalization and trafficking, lysosomal processing, payload sensitivity, and stromal barriers, with losartan identified as enhancing HER2-ADC activity in preclinical models. The central question for clinicians is whether rechallenge with T-DXd constitutes a legitimate line of therapy in HER2-positive metastatic disease specifically when the prior discontinuation was driven by toxicity rather than progression.

Discussed by: @kazuki_nozawa, @stolaney1

→ View representative tweet

First-line ivonescimab plus chemotherapy hits 80% ORR in advanced TNBC, but the anti-VEGF track record invites caution

This phase 2 trial evaluated first-line ivonescimab plus chemotherapy in 36 women with previously untreated, locally advanced or metastatic triple-negative breast cancer; after 22.1 months' median follow-up, the objective response rate was 80%, including two complete responses, with mPFS of 15.2 months. In CPS<10 disease, ORR was 79.3% and mPFS was 13 months. Treatment-related adverse events occurred in 36 (100.0%) patients, with grade ≥3 events in 21 (58.3%), and no treatment-related deaths. Oncologists contextualizing these results note that bevacizumab won approval on PFS in 2008, never improved overall survival, and lost its breast cancer indication in 2011, framing the question of whether a single-arm 80% ORR in PD-L1-low TNBC should change clinical thinking before a phase 3 overall survival readout is available.

Discussed by: @stolaney1, @DrBarbiOnc, @JaniceTNBCmets, @OncoAlert

→ View representative tweet

GLP-1 receptor agonists and breast cancer incidence: a JCO OP signal meets a borderline hazard ratio

A report in JCO Oncology Practice describes GLP-1 agonists as associated with a significant reduction in breast cancer incidence in women, but a large real-world study of obese adults without diabetes places that signal in context: obesity-associated cancer occurred in 0.54% versus 0.90% of participants (HR 0.59), with the strongest signals seen for multiple myeloma (HR 0.37), pancreatic cancer (HR 0.40), endometrial cancer (HR 0.42), and colorectal cancer (HR 0.49), while breast cancer showed only a borderline signal (HR 0.83; 95% CI 0.69–0.996). The debate among clinicians centers on whether that borderline breast cancer hazard ratio is strong enough to represent more than a confounded observational association.

Discussed by: @OncoAlert, @ChandrakanthMv

→ View representative tweet

🔥 Top Ranked Tweets

Elad Sharon @EladSharonMD

RT @ALLIANCE_org: 🎉 FDA APPROVES palbociclib combo for HR+, HER2+ advanced breast cancer!
Based on the PATINA trial (AFT-38), adding palbociclib to maintenance therapy extended progression-free survival by 15 months (from 29.1 to 44.3 mos). A huge win for patient care! 💪 https://t.co/8m3epmPPsY https://t.co/Zs395hHJQ6

🔖 1 ❤️ 13 🔁 5 👁 1,096